|
gptkbp:instanceOf
|
gptkb:drug
sedative
nonbenzodiazepine
|
|
gptkbp:approvalYear
|
2004
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N05CF04
|
|
gptkbp:brand
|
gptkb:Lunesta
|
|
gptkbp:CASNumber
|
138729-47-2
|
|
gptkbp:category
|
sleep aid
benzodiazepine
sedative
|
|
gptkbp:chemicalFormula
|
S-enantiomer of zopiclone
|
|
gptkbp:contraindication
|
severe liver impairment
hypersensitivity to eszopiclone
|
|
gptkbp:developedBy
|
gptkb:Sepracor
|
|
gptkbp:drugClass
|
cyclopyrrolone
|
|
gptkbp:eliminationHalfLife
|
6 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstPassMetabolism
|
yes
|
|
gptkbp:hasMolecularFormula
|
C17H17ClN6O3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
eszopiclone
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor agonist
|
|
gptkbp:meltingPoint
|
203–204 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
52–59%
|
|
gptkbp:PubChem_CID
|
106829
96313
|
|
gptkbp:riskFactor
|
dependence
withdrawal symptoms
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
headache
drowsiness
dry mouth
unpleasant taste
|
|
gptkbp:synonym
|
gptkb:S-zopiclone
(+)-zopiclone
|
|
gptkbp:UNII
|
U5TYW8N95T
|
|
gptkbp:usedFor
|
treatment of insomnia
|
|
gptkbp:bfsParent
|
gptkb:4-aminobutanoic_acid
|
|
gptkbp:bfsLayer
|
6
|